Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schewe, D. M.
Right arrow Articles by Allgayer, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schewe, D. M.
Right arrow Articles by Allgayer, H.
Clinical Cancer Research Vol. 11, 8538-8548, December 15, 2005
© 2005 American Association for Cancer Research


Human Cancer Biology

Combination Analysis of Activator Protein-1 Family Members, Sp1 and an Activator Protein-2{alpha}-Related Factor Binding to Different Regions of the Urokinase Receptor Gene in Resected Colorectal Cancers

Denis Martin Schewe3, Tobias Biller1, Gabriele Maurer4, Irfan A. Asangani1, Joerg H. Leupold1, Ernst R. Lengyel5, Stefan Post2 and Heike Allgayer1

Authors' Affiliations: 1 Department of Experimental Surgery and Molecular Oncology, Universitaetsklinikum Mannheim and 2 Department of Surgery Mannheim, University of Heidelberg, Heidelberg, 3 Department of Pediatrics, Dr. v. Haunersches Kinderspital, 4 Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany, and 5 Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois

Requests for reprints: Heike Allgayer, Department of Experimental Surgery/Molecular Oncology, Universitätsklinikum Mannheim, University of Heidelberg, 68167 Mannheim, Germany. Phone: 49-621-383-2226; Fax: 49-621-383-3809/1938; E-mail: DAllgayer{at}aol.com.

Purpose: Studies on the transactivation of genes via promoter elements have mostly been done on cell lines rather than resected tissues. This, however, is essential to address an in vivo or clinical relevance. We have previously shown tumor-specific binding of Sp1 and an activator protein (AP)-2–related factor to promoter region –152/–135 of the metastasis-related u-PAR gene in 60% of in vivo–resected cancer tissues. Cell lines have implicated an additional role, and potential synergism, of an AP-1 region (–190/–171) in u-PAR regulation. This study was done to (a) analyze AP-1 binding to this region in resected tumor and normal tissues, and define subgroups in which it is tumor-specific, and (b) to analyze transcription factor–binding patterns to both promoter motifs in resected tissues, supporting synergism, and draw first prognostic conclusions.

Experimental Design: In 103 patients with colorectal cancer, electrophoretic mobility shift assay/supershift analysis for u-PAR promoter region –190/–171 was done in tumors and normal tissues. In 71 patients, region –152/–135 was also analyzed. U-PAR protein was measured by ELISA.

Results: Tumor-specific AP-1 binding to region –190/–171 of the u-PAR promoter was found in 40% of patients. Subgroup analysis showed tumor-specific binding for c-Fos in 58%, for c-Jun in 50%, for JunD in 39%, and for Fra-1 in 4% of cases. AP-1 binding correlated significantly with u-PAR protein amounts in both normal and tumor tissues (P < 0.001), in contrast to a tumor-specific correlation with u-PAR of the AP-2/Sp1 region. In analyses for both promoter regions, 62% of cancers showed simultaneous binding for AP-1, AP-2, and Sp1, 11% for AP-1 and AP-2, 16% for AP-2 and Sp1, 4% for AP-2 only, 3% for AP-1 only, and 0% for Sp1 only. The binding of AP-1, AP-2, and Sp1 correlated significantly with each other (P < 0.001), the combination of AP-1 and AP-2 showing the highest correlation with u-PAR (P = 0.008). Preliminary survival analysis indicated a trend for poorer prognosis for binding of all three transcription factors.

Conclusion: This is the first study differentiating transcription factor–binding to two important u-PAR promoter regions in a large series of resected tumors and normal tissues. The AP-1 site seems to be a less tumor-specific regulator than the Sp1/AP-2 motif. Nevertheless, data corroborate the hypothesis of synergism between both elements in resected tumors.




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
J. H. Leupold, I. Asangani, G. D. Maurer, E. Lengyel, S. Post, and H. Allgayer
Src Induces Urokinase Receptor Gene Expression and Invasion/Intravasation via Activator Protein-1/p-c-Jun in Colorectal Cancer
Mol. Cancer Res., May 1, 2007; 5(5): 485 - 496.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. D. Maurer, J. H. Leupold, D. M. Schewe, T. Biller, R. E. Kates, H.-M. Hornung, U. Lau-Werner, S. Post, and H. Allgayer
Analysis of Specific Transcriptional Regulators as Early Predictors of Independent Prognostic Relevance in Resected Colorectal Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1123 - 1132.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2005 by the American Association for Cancer Research.